• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Kinetics of Sulbactam Hydrolysis by β-Lactamases, and Kinetics of β-Lactamase Inhibition by Sulbactam.β-内酰胺酶对舒巴坦的水解动力学及舒巴坦对β-内酰胺酶的抑制动力学。
Antimicrob Agents Chemother. 2017 Nov 22;61(12). doi: 10.1128/AAC.01612-17. Print 2017 Dec.
2
Targeting Multidrug-Resistant spp.: Sulbactam and the Diazabicyclooctenone β-Lactamase Inhibitor ETX2514 as a Novel Therapeutic Agent.针对多重耐药 spp.:舒巴坦和二氮杂二环辛酮 β-内酰胺酶抑制剂 ETX2514 作为一种新型治疗剂。
mBio. 2019 Mar 12;10(2):e00159-19. doi: 10.1128/mBio.00159-19.
3
Reversibility of Covalent, Broad-Spectrum Serine β-Lactamase Inhibition by the Diazabicyclooctenone ETX2514.二氮杂双环辛烯酮ETX2514对共价、广谱丝氨酸β-内酰胺酶抑制作用的可逆性
ACS Infect Dis. 2017 Nov 10;3(11):833-844. doi: 10.1021/acsinfecdis.7b00113. Epub 2017 Aug 28.
4
Activity of the β-Lactamase Inhibitor LN-1-255 against Carbapenem-Hydrolyzing Class D β-Lactamases from Acinetobacter baumannii.β-内酰胺酶抑制剂 LN-1-255 对鲍曼不动杆菌碳青霉烯水解酶 D 类β-内酰胺酶的活性。
Antimicrob Agents Chemother. 2017 Oct 24;61(11). doi: 10.1128/AAC.01172-17. Print 2017 Nov.
5
Activity of avibactam against Enterobacter cloacae producing an extended-spectrum class C β-lactamase enzyme.阿维巴坦对产超广谱C类β-内酰胺酶的阴沟肠杆菌的活性。
J Antimicrob Chemother. 2014 Nov;69(11):2942-6. doi: 10.1093/jac/dku237. Epub 2014 Jun 30.
6
Kinetics of turnover of cefotaxime by the Enterobacter cloacae P99 and GCl beta-lactamases: two free enzyme forms of the P99 beta-lactamase detected by a combination of pre- and post-steady state kinetics.阴沟肠杆菌P99和GClβ-内酰胺酶对头孢噻肟的周转动力学:通过稳态前和稳态后动力学相结合检测到P99β-内酰胺酶的两种游离酶形式。
Biochemistry. 2004 Mar 9;43(9):2664-72. doi: 10.1021/bi030212j.
7
Molecular basis of selective inhibition and slow reversibility of avibactam against class D carbapenemases: a structure-guided study of OXA-24 and OXA-48.阿维巴坦对D类碳青霉烯酶的选择性抑制和缓慢可逆性的分子基础:OXA - 24和OXA - 48的结构导向研究
ACS Chem Biol. 2015 Feb 20;10(2):591-600. doi: 10.1021/cb500703p. Epub 2014 Dec 4.
8
A kinetic study of NMC-A beta-lactamase, an Ambler class A carbapenemase also hydrolyzing cephamycins.NMC-Aβ-内酰胺酶的动力学研究,一种也能水解头孢霉素的安布勒A类碳青霉烯酶。
FEMS Microbiol Lett. 1996 Sep 15;143(1):29-33. doi: 10.1111/j.1574-6968.1996.tb08457.x.
9
Biochemical Characterization of QPX7728, a New Ultrabroad-Spectrum Beta-Lactamase Inhibitor of Serine and Metallo-Beta-Lactamases.新型超广谱丝氨酸和金属β-内酰胺酶抑制剂 QPX7728 的生化特性研究。
Antimicrob Agents Chemother. 2020 May 21;64(6). doi: 10.1128/AAC.00130-20.
10
Sulbactam-durlobactam: a β-lactam/β-lactamase inhibitor combination targeting .舒巴坦-他唑巴坦:一种针对. 的β-内酰胺/β-内酰胺酶抑制剂复方制剂。
Future Microbiol. 2024;19(7):563-576. doi: 10.2217/fmb-2023-0248. Epub 2024 Mar 1.

引用本文的文献

1
New β-Lactam/β-Lactamase Inhibitor Combination Antibiotics.新型β-内酰胺/β-内酰胺酶抑制剂联合抗生素
Pathogens. 2025 Mar 24;14(4):307. doi: 10.3390/pathogens14040307.
2
Sulbactam for carbapenem-resistant infections: a literature review.舒巴坦用于耐碳青霉烯类感染:一项文献综述。
JAC Antimicrob Resist. 2025 Apr 12;7(2):dlaf055. doi: 10.1093/jacamr/dlaf055. eCollection 2025 Apr.
3
Dynamic optimization elucidates higher-level pathogenicity strategies of .动态优化阐明了……的更高层次的致病策略。 你提供的原文似乎不完整,“of”后面缺少具体内容。
Microlife. 2025 Mar 13;6:uqaf005. doi: 10.1093/femsml/uqaf005. eCollection 2025.
4
In vitro activity and resistance mechanisms of novel antimicrobial agents against metallo-β-lactamase producers.新型抗菌剂对金属β-内酰胺酶产生菌的体外活性及耐药机制
Eur J Clin Microbiol Infect Dis. 2025 May;44(5):1041-1068. doi: 10.1007/s10096-025-05080-1. Epub 2025 Mar 10.
5
A microbiological and structural analysis of the interplay between sulbactam/durlobactam and imipenem against penicillin-binding proteins (PBPs) of spp.舒巴坦/度洛巴坦与亚胺培南对[具体菌种]青霉素结合蛋白(PBPs)相互作用的微生物学和结构分析
Antimicrob Agents Chemother. 2025 Apr 2;69(4):e0162724. doi: 10.1128/aac.01627-24. Epub 2025 Mar 4.
6
An overview of sulbactam-durlobactam approval and implications in advancing therapeutics for hospital-acquired and ventilator-associated pneumonia by complex: A narrative review.舒巴坦-度洛巴坦获批情况概述及其对推进医院获得性肺炎和呼吸机相关性肺炎治疗方案的影响:一项叙述性综述。
Health Sci Rep. 2024 Sep 9;7(9):e70066. doi: 10.1002/hsr2.70066. eCollection 2024 Sep.
7
Treatment of infections caused by carbapenem-resistant .治疗耐碳青霉烯类抗生素的感染。
Front Cell Infect Microbiol. 2024 Jul 18;14:1395260. doi: 10.3389/fcimb.2024.1395260. eCollection 2024.
8
The Growing Threat of NDM-Producing Escherichia coli With Penicillin-Binding Protein 3 Mutations in the United States-Is There a Potential Role for Durlobactam?美国具有青霉素结合蛋白 3 突变的产新德里金属-β-内酰胺酶大肠杆菌的日益增长威胁——杜拉菌素是否有潜在作用?
Clin Infect Dis. 2024 Oct 15;79(4):834-837. doi: 10.1093/cid/ciae229.
9
Characterization of complex isolates and microbiological outcome for patients treated with sulbactam-durlobactam in a phase 3 trial (ATTACK).在一项 3 期试验(ATTACK)中,使用舒巴坦-多利培南治疗的患者的复杂分离株特征及微生物学结局。
Antimicrob Agents Chemother. 2024 May 2;68(5):e0169823. doi: 10.1128/aac.01698-23. Epub 2024 Apr 3.
10
Sulbactam-durlobactam: a β-lactam/β-lactamase inhibitor combination targeting .舒巴坦-他唑巴坦:一种针对. 的β-内酰胺/β-内酰胺酶抑制剂复方制剂。
Future Microbiol. 2024;19(7):563-576. doi: 10.2217/fmb-2023-0248. Epub 2024 Mar 1.

本文引用的文献

1
ETX2514 is a broad-spectrum β-lactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including Acinetobacter baumannii.ETX2514 是一种广谱β-内酰胺酶抑制剂,用于治疗包括鲍曼不动杆菌在内的耐药革兰氏阴性菌。
Nat Microbiol. 2017 Jun 30;2:17104. doi: 10.1038/nmicrobiol.2017.104.
2
Antimicrobial activity of tigecycline and cefoperazone/sulbactam tested against 18,386 Gram-negative organisms from Europe and the Asia-Pacific region (2013-2014).针对来自欧洲和亚太地区的18386株革兰氏阴性菌(2013 - 2014年)检测替加环素和头孢哌酮/舒巴坦的抗菌活性。
Diagn Microbiol Infect Dis. 2017 Jun;88(2):177-183. doi: 10.1016/j.diagmicrobio.2017.02.020. Epub 2017 Mar 6.
3
Efficacy of sulbactam for the treatment of Acinetobacter baumannii complex infection: A systematic review and meta-analysis.舒巴坦治疗鲍曼不动杆菌复合群感染的疗效:一项系统评价和荟萃分析。
J Infect Chemother. 2017 May;23(5):278-285. doi: 10.1016/j.jiac.2017.01.005. Epub 2017 Feb 13.
4
β-Lactams and β-Lactamase Inhibitors: An Overview.β-内酰胺类与β-内酰胺酶抑制剂:概述
Cold Spring Harb Perspect Med. 2016 Aug 1;6(8):a025247. doi: 10.1101/cshperspect.a025247.
5
β-Lactam Antibiotics Renaissance.β-内酰胺类抗生素的复兴。
Antibiotics (Basel). 2014 May 9;3(2):193-215. doi: 10.3390/antibiotics3020193.
6
Kinetic Study of Laboratory Mutants of NDM-1 Metallo-β-Lactamase and the Importance of an Isoleucine at Position 35.NDM-1金属β-内酰胺酶实验室突变体的动力学研究及35位异亮氨酸的重要性
Antimicrob Agents Chemother. 2016 Mar 25;60(4):2366-72. doi: 10.1128/AAC.00531-15. Print 2016 Apr.
7
A resurgence of β-lactamase inhibitor combinations effective against multidrug-resistant Gram-negative pathogens.β-内酰胺酶抑制剂复方制剂对抗多重耐药革兰氏阴性病原体的卷土重来。
Int J Antimicrob Agents. 2015 Nov;46(5):483-93. doi: 10.1016/j.ijantimicag.2015.08.011. Epub 2015 Sep 25.
8
Molecular mechanisms of sulbactam antibacterial activity and resistance determinants in Acinetobacter baumannii.鲍曼不动杆菌中舒巴坦抗菌活性及耐药决定因素的分子机制
Antimicrob Agents Chemother. 2015 Mar;59(3):1680-9. doi: 10.1128/AAC.04808-14. Epub 2015 Jan 5.
9
OXA β-lactamases.OXA β-内酰胺酶
Clin Microbiol Rev. 2014 Apr;27(2):241-63. doi: 10.1128/CMR.00117-13.
10
Resistance surveillance program report for selected European nations (2011).选定欧洲国家(2011 年)耐药监测计划报告。
Diagn Microbiol Infect Dis. 2014 Apr;78(4):429-36. doi: 10.1016/j.diagmicrobio.2013.10.008. Epub 2013 Oct 14.

β-内酰胺酶对舒巴坦的水解动力学及舒巴坦对β-内酰胺酶的抑制动力学。

Kinetics of Sulbactam Hydrolysis by β-Lactamases, and Kinetics of β-Lactamase Inhibition by Sulbactam.

机构信息

Entasis Therapeutics, Waltham, Massachusetts, USA

出版信息

Antimicrob Agents Chemother. 2017 Nov 22;61(12). doi: 10.1128/AAC.01612-17. Print 2017 Dec.

DOI:10.1128/AAC.01612-17
PMID:28971872
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5700308/
Abstract

Sulbactam is one of four β-lactamase inhibitors in current clinical use to counteract drug resistance caused by degradation of β-lactam antibiotics by these bacterial enzymes. As a β-lactam itself, sulbactam is susceptible to degradation by β-lactamases. I investigated the Michaelis-Menten kinetics of sulbactam hydrolysis by 14 β-lactamases, representing clinically widespread groups within all four Ambler classes, i.e., CTX-M-15, KPC-2, SHV-5, and TEM-1 for class A; IMP-1, NDM-1, and VIM-1 for class B; ADC-7, AmpC, and P99 for class C; and OXA-10, OXA-23, OXA-24, and OXA-48 for class D. All of the β-lactamases were able to hydrolyze sulbactam, although they varied widely in their kinetic constants for the reaction, even within each class. I also investigated the inactivation kinetics of the inhibition of these enzymes by sulbactam. The class A β-lactamases varied widely in their susceptibility to inhibition, the class C and D enzymes were very weakly inhibited, and the class B enzymes were essentially or completely unaffected. In addition, we measured the sulbactam turnover number, the sulbactam/enzyme molar ratio required for complete inhibition of each enzyme. Class C enzymes had the lowest turnover numbers, class A enzymes varied widely, and class D enzymes had very high turnover numbers. These results are valuable for understanding which β-lactamases ought to be well inhibited by sulbactam. Moreover, since sulbactam has intrinsic antibacterial activity against species pathogens, these results contribute to understanding β-lactamase-mediated sulbactam resistance in , especially due to the action of the widespread class D enzymes.

摘要

舒巴坦是目前临床使用的四种β-内酰胺酶抑制剂之一,用于抵抗这些细菌酶对β-内酰胺抗生素的降解所导致的药物耐药性。作为一种β-内酰胺,舒巴坦本身容易被β-内酰胺酶降解。我研究了 14 种β-内酰胺酶对舒巴坦水解的米氏动力学,这些酶代表了所有四个 Ambler 类别的临床广泛群体,即 CTX-M-15、KPC-2、SHV-5 和 TEM-1 为 A 类;IMP-1、NDM-1 和 VIM-1 为 B 类;ADC-7、AmpC 和 P99 为 C 类;以及 OXA-10、OXA-23、OXA-24 和 OXA-48 为 D 类。所有的β-内酰胺酶都能够水解舒巴坦,尽管它们在反应的动力学常数上差异很大,甚至在每个类别内也是如此。我还研究了这些酶被舒巴坦抑制的失活动力学。A 类β-内酰胺酶对抑制的敏感性差异很大,C 类和 D 类酶的抑制作用很弱,而 B 类酶基本上或完全不受影响。此外,我们测量了舒巴坦的周转数,即每个酶完全抑制所需的舒巴坦/酶摩尔比。C 类酶的周转数最低,A 类酶差异很大,D 类酶的周转数非常高。这些结果对于理解哪些β-内酰胺酶应该被舒巴坦很好地抑制是有价值的。此外,由于舒巴坦对 种病原体具有内在的抗菌活性,这些结果有助于理解β-内酰胺酶介导的舒巴坦耐药性,尤其是由于广泛存在的 D 类酶的作用。